Unveiling Cancer Risk in ANCA-Associated Vasculitis: Result from the Turkish Vasculitis Study Group (TRVaS)
Abstract Aim:To investigate cancer incidence in patients with ANCA-associated vasculitides (AAV), compare it with the age/sex-spesific cancer risk of Turkish population, explore independent risk factors associated with cancer. Methods:This multicenter, incidence case-control study was conducted using TRVaS registry. AAV patients without cancer history before AAV diagnosis were included. Demographic and AAV-related data of patients with and without an incident cancer were compared. Standardized cancer incidence rates were calculated using age/sex-spesific 2017 Turkish National Cancer Registry data for cancers (excluding non-melanoma skin cancers). Cox regression was performed to find factors related to incident cancers in AAV patients. Results:Of 461 AAV patients (236[51.2%] male), 19 had incident cancers after 2022.8 patient-years follow-up. Median(IQR) disease duration was 3.4(5.5) years, and 58(12.6%) patients died [7 with cancer and 1 without cancer (log-rank,p=0.04)]. Cancer-diagnosed patients were older, mostly male, and more likely to have anti-PR3-ANCA positivity. The cumulative cyclophosphamide dose was similar in patients with and without cancer. Overall cancer risk in AAV was 2.1(SIR)(1.3-3.2),p=0.004); lung and head-neck [primary target sites for AAV] cancers were the most common. In Cox regression, male sex and ≥60 years of age at AAV diagnosis were associated with increased cancer risk, while receiving rituximab was associated with decreased cancer risk. Conclusions:Cancer risk was 2.1-times higher in AAV patients than the age/sex-spesific cancer risk of Turkish population, despite a high rate of rituximab use and lower dose of cyclophosphamide doses. Vigilance in cancer screening for AAV patients covering lung, genitourinary, and head-neck regions, particularly in males and the elderly, is vital..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ResearchSquare.com - (2024) vom: 23. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bilgin, Emre [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-3860558/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA042262348 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA042262348 | ||
| 003 | DE-627 | ||
| 005 | 20240124130904.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240124s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-3860558/v1 |2 doi | |
| 035 | |a (DE-627)XRA042262348 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-3860558/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bilgin, Emre |e verfasserin |0 (orcid)0000-0002-2260-4660 |4 aut | |
| 245 | 1 | 0 | |a Unveiling Cancer Risk in ANCA-Associated Vasculitis: Result from the Turkish Vasculitis Study Group (TRVaS) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Aim:To investigate cancer incidence in patients with ANCA-associated vasculitides (AAV), compare it with the age/sex-spesific cancer risk of Turkish population, explore independent risk factors associated with cancer. Methods:This multicenter, incidence case-control study was conducted using TRVaS registry. AAV patients without cancer history before AAV diagnosis were included. Demographic and AAV-related data of patients with and without an incident cancer were compared. Standardized cancer incidence rates were calculated using age/sex-spesific 2017 Turkish National Cancer Registry data for cancers (excluding non-melanoma skin cancers). Cox regression was performed to find factors related to incident cancers in AAV patients. Results:Of 461 AAV patients (236[51.2%] male), 19 had incident cancers after 2022.8 patient-years follow-up. Median(IQR) disease duration was 3.4(5.5) years, and 58(12.6%) patients died [7 with cancer and 1 without cancer (log-rank,p=0.04)]. Cancer-diagnosed patients were older, mostly male, and more likely to have anti-PR3-ANCA positivity. The cumulative cyclophosphamide dose was similar in patients with and without cancer. Overall cancer risk in AAV was 2.1(SIR)(1.3-3.2),p=0.004); lung and head-neck [primary target sites for AAV] cancers were the most common. In Cox regression, male sex and ≥60 years of age at AAV diagnosis were associated with increased cancer risk, while receiving rituximab was associated with decreased cancer risk. Conclusions:Cancer risk was 2.1-times higher in AAV patients than the age/sex-spesific cancer risk of Turkish population, despite a high rate of rituximab use and lower dose of cyclophosphamide doses. Vigilance in cancer screening for AAV patients covering lung, genitourinary, and head-neck regions, particularly in males and the elderly, is vital. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Yıldırım, Tuba Demirci |4 aut | |
| 700 | 1 | |a Ulusoy, Bahar Özdemir |4 aut | |
| 700 | 1 | |a Öğüt, Tahir Saygın |4 aut | |
| 700 | 1 | |a Karabacak, Murat |4 aut | |
| 700 | 1 | |a Çağdaş, Öznur Sadioğlu |4 aut | |
| 700 | 1 | |a Yıldırım, Reşit |4 aut | |
| 700 | 1 | |a Güven, Deniz Can |4 aut | |
| 700 | 1 | |a Akleylek, Cansu |4 aut | |
| 700 | 1 | |a Ediboğlu, Elif |4 aut | |
| 700 | 1 | |a Kutu, Muhammet Emin |4 aut | |
| 700 | 1 | |a Özgür, Duygu |4 aut | |
| 700 | 1 | |a Kardaş, Riza Can |4 aut | |
| 700 | 1 | |a Bölek, Ertuğrul Çağrı |4 aut | |
| 700 | 1 | |a Uzun, Gül Sandal |4 aut | |
| 700 | 1 | |a Özsoy, Zehra |4 aut | |
| 700 | 1 | |a Sarıyıldız, Emine |4 aut | |
| 700 | 1 | |a Ayan, Gizem |4 aut | |
| 700 | 1 | |a Armağan, Berkan |4 aut | |
| 700 | 1 | |a Erden, Abdussamet |4 aut | |
| 700 | 1 | |a Kılıç, Levent |4 aut | |
| 700 | 1 | |a Erbasan, Funda |4 aut | |
| 700 | 1 | |a Alibaz-Öner, Fatma |4 aut | |
| 700 | 1 | |a Aşıcıoğlu, Ebru |4 aut | |
| 700 | 1 | |a Yazici, Ayten |4 aut | |
| 700 | 1 | |a Bilge, Nazife Şule |4 aut | |
| 700 | 1 | |a Küçük, Hamit |4 aut | |
| 700 | 1 | |a Çelik, Selda |4 aut | |
| 700 | 1 | |a Bes, Cemal |4 aut | |
| 700 | 1 | |a Akar, Servet |4 aut | |
| 700 | 1 | |a Yılmaz, Neslihan |4 aut | |
| 700 | 1 | |a Kaşifoğlu, Timuçin |4 aut | |
| 700 | 1 | |a Cefle, Ayşe |4 aut | |
| 700 | 1 | |a Direskeneli, Haner |4 aut | |
| 700 | 1 | |a Yazısız, Veli |4 aut | |
| 700 | 1 | |a Dizdar, Ömer |4 aut | |
| 700 | 1 | |a Omma, Ahmet |4 aut | |
| 700 | 1 | |a Önen, Fatoş |4 aut | |
| 700 | 1 | |a Karadağ, Ömer |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2024) vom: 23. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-3860558/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 01 | ||